Thermo Fisher bags single-use bioreactor tech partner Finesse

By Dan Stanton contact

- Last updated on GMT

Image: iStock/designer491
Image: iStock/designer491
Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.

The deal announced yesterday, adds bioprocess management technology Finesse Solutions to Thermo Fisher’s life sciences business.

CEO Marc Casper said the Santa Clara, California-based firm has been a technology partner since 2013, and its universal control system which combines with Thermo Fisher’s own single-use technologies will “strengthen our position in the high-growth bioproduction market.”

Finesse’s Smart technology suite offers a range of data management software, and bioreactor controllers and sensors which allow bioprocessing firms and drugmakers to configurate biomanufacturing processes from labscale to cGMP-compliant production.

Finesse generated around $50m in revenue last year. Financial details of the deal were not divulged, but Thermo Fisher expects the deal to close in the next few days, having received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

M&A

The deal is the latest in a string of acquisitions made in the life science space by Thermo Fisher.

Last year the firm bought biological analysis firm Affymetrix​ for $1.3bn, analytical instrument firm FEI Company​ for $4.2bn, and stem cell tech and reagent business MTI-GlobalStem​. 2015 saw the company add disposable technology firm ASI to its bioprocessing arsenal for $300m, and a year earlier Life Technologies​ was acquired for $13bn.

Thermo Fisher was also rumoured to be interested in buying downstream disposable tech firm Pall Corporation – since acquired by Danaher for $13bn​ – and last summer was allegedly eyeing up Illumina for $30bn​.

During a call to discuss its Q4 results late last month, Casper told investors his firm continued to look at a number of M&A opportunities.

“The industry is incredibly fragmented,”​ he said. “So we follow our strategy of looking at things that will strengthen the company strategically, clearly be understood and valued by our customers and create shareholder value, with the primary metric being return on invested capital.”

Related news

Show more

Related products

show more

An Intense Focus on Perfusion

An Intense Focus on Perfusion

MilliporeSigma | 09-Oct-2017 | Technical / White Paper

Continuous manufacturing technologies are seeing increased industry uptake, particularly perfusion systems and, increasingly, intensified perfusion. Perfusion...

A Trusted Resin Provider For Over 35 Years

A Trusted Resin Provider For Over 35 Years

Purolite Life Sciences | 18-Sep-2017

Watch our video above to learn more about the history of Purolite Life Sciences.To discuss how we can assist your journey to process excellence, please...

The Next Stage – Eppendorfs new Mastercycler X50

The Next Stage – Eppendorfs new Mastercycler X50

Eppendorf for Bioprocess – Solutions that grow with you | 05-Sep-2017 | Application Note

The Mastercycler X50 is Eppendorf's new PCR cycler with lots of new benefits. Not only can you heat with 10°C/s, you can also optimize two different...

Related suppliers